Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company's Biotech Division. The patent protects technology for the treatment of neuromuscular diseases through expression of the human Klotho protein, according to a company press release.
The patent strengthens the intellectual property supporting Greenland Mines' Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (ALS) and other neuromuscular disorders.
Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of a previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and Biotech, including the KLTO-202 primary indication for ALS.
The company's strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The full press release is available at https://nnw.fm/PVbbH. For the latest news and updates relating to GRML, visit the company's newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors set forth under "Risk Factors" in the company's SEC filings. The company undertakes no duty to update this information unless required by law.
